Cytokinetics Inc. (CYTK)
Health Care ยท Pharmaceutical Preparations
Cytokinetics Inc. (CYTK) is listed on Nasdaq, where its shares have traded since April 29, 2004. SentiSense covers Cytokinetics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Robert Blum is its chief executive officer. The company reports 673 employees, and its corporate website is www.cytokinetics.com.
About Cytokinetics Inc.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 467 institutions reported holding CYTK, with 160.3 million shares worth $13.6 billion in aggregate. The largest reported holders were T. Rowe Price, BlackRock and Vanguard. Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter.
More on CYTK
- CYTK sentiment: whether news and social coverage of Cytokinetics Inc. leans bullish or bearish, and the stories driving it.
- CYTK ownership: all 467 reporting institutions, plus insider and congressional trades.
- CYTK financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Cytokinetics Inc.: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Cytokinetics Inc. do?
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.
What sector is CYTK in?
SentiSense classifies Cytokinetics Inc. in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does CYTK stock trade?
Cytokinetics Inc. (CYTK) is listed on Nasdaq, where its shares have traded since April 29, 2004.
Who is the CEO of Cytokinetics Inc.?
Robert Blum is the chief executive officer of Cytokinetics Inc..